From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices by Boeri M, Szegvari B, Hauber B, Mange B, Mountian I, Schiff M, Maniadakis N

Get full text

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis by Taylor, P, Tanaka, Y, Cardoso, A, Zhong, J, Chen, Y, Workman, J, Morales, L, Schiff, M

Efficacy and safety of monotherapy with sirukumab, an anti-IL-6 cytokine monoclonal antibody, compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid... by Taylor, P, Schiff, M, Wang, Q, Jiang, Y, Kurrasch, R, Daga, S, Rao, R, Hsu, B, Tak, P

Efficacy and safety of monotherapy with sirukumab compared to adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-... by Taylor, P, Schiff, M, Wang, Q, Jiang, Y, Zhuang, Y, Kurrasch, R, Daga, S, Rao, R, Tak, P, Hsu, B

CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL by Wordsworth, P, van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Ballal, S, Kupper, H, Wong, R, Sieper, J

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-... by van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Wordsworth, P, Ballal, S, Kupper, H, Wong, R, Sieper, J, Grp, A

Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas by Wordsworth, P, Dijkmans, B, van der Heijde, D, Davis, J, Schiff, M, Kivitz, A, Sieper, J, Mease, P, Kupper, H, Wong, R, Grp, A

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. by van der Heijde, D, Kivitz, A, Schiff, M, Sieper, J, Dijkmans, B, Braun, J, Dougados, M, Wordsworth, P, Wong, R, Kupper, H, Davis, J

Mitochondrial double-stranded RNA triggers antiviral signalling in humans by Dhir, A, Dhir, S, Borowski, LS, Jimenez, L, Teitell, M, Rötig, A, Crow, YJ, Rice, GI, Duffy, D, Tamby, C, Nojima, T, Munnich, A, Schiff, M, De Almeida, CR, Rehwinkel, J, Dziembowski, A, Szczesny, RJ, Proudfoot, NJ

Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? by Mastantuono, E, Repp, B, Alston, CL, Schiff, M, Haack, TB, Rotig, A, Ardissone, A, Lombes, A, Catarino, CB, Diodato, D, Schottmann, G, Poulton, J, Burlina, A, Jonckheere, A, Munnich, A, Ghezzi, D, Rokicki, D, Wellesley, D, Martinelli, D, Lamantea, E, Ostergaard, E, Pronicka, E, Pierre, G, Smeets, HJ, Scurr, I, De Coo, IF, Moroni, I, Smet, J, Mayr, JA, De Meirleir, L, Schuelke, M, Zeviani, M, McFarland, R, Seneca, S, Klopstock, T, Meitinger, T, Strom, TM, Herberg, U, Sperl, W, Nassogne, M, Ling, H, Fang, F, Freisinger, P, Van Coster, R, Taylor, RW, Haberle, J, Vockley, J, Prokisch, H, Wortmann, S